Literature DB >> 34047859

The Landmark Series: Preoperative Therapy for Pancreatic Cancer.

Sameer H Patel1, Matthew H G Katz2, Syed A Ahmad3.   

Abstract

The surgical treatment of pancreas ductal adenocarcinoma (PDAC) is plagued by high rates of distant recurrences despite complete resection, highlighting the importance of systemic therapy. Historically, patients with PDAC have been treated with postoperative therapy, but this sequencing strategy can be associated with the inability to complete therapy due to perioperative complications and prolonged recovery. In addition, a subset of patients progress early, irrespective of whether surgery is performed, highlighting the systemic nature of this disease. Preoperative therapy has increasingly been utilized in clinical practice, but studies examining its benefits are limited. In this Landmark Series, we will review seminal studies for resectable and borderline resectable PDAC.

Entities:  

Year:  2021        PMID: 34047859     DOI: 10.1245/s10434-021-10075-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  54 in total

1.  Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?

Authors:  Thomas A Aloia; Thomas E Aloia; Jeffrey E Lee; Jean-Nicolas Vauthey; Eddie K Abdalla; Robert A Wolff; Gauri R Varadhachary; James L Abbruzzese; Christopher H Crane; Douglas B Evans; Peter W T Pisters
Journal:  J Am Coll Surg       Date:  2007-03       Impact factor: 6.113

2.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

3.  Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification.

Authors:  Ching-Wei D Tzeng; Matthew H G Katz; Jason B Fleming; Jeffrey E Lee; Peter W T Pisters; Holly M Holmes; Gauri R Varadhachary; Robert A Wolff; James L Abbruzzese; Jean-Nicolas Vauthey; Thomas A Aloia
Journal:  J Gastrointest Surg       Date:  2013-10-16       Impact factor: 3.452

4.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

5.  Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.

Authors:  Ariella M Altman; Keith Wirth; Schelomo Marmor; Emil Lou; Katherine Chang; Jane Y C Hui; Todd M Tuttle; Eric H Jensen; Jason W Denbo
Journal:  Ann Surg Oncol       Date:  2019-07-16       Impact factor: 5.344

6.  Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Chandrajit P Raut; Jennifer F Tseng; Charlotte C Sun; Huamin Wang; Robert A Wolff; Christopher H Crane; Rosa Hwang; Jean-Nicolas Vauthey; Eddie K Abdalla; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

7.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Authors:  Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

8.  Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study.

Authors:  Georgios Gemenetzis; Vincent P Groot; Jun Yu; Ding Ding; Jonathan A Teinor; Ammar A Javed; Laura D Wood; Richard A Burkhart; John L Cameron; Martin A Makary; Matthew J Weiss; Jin He; Christopher L Wolfgang
Journal:  Ann Surg       Date:  2018-09       Impact factor: 12.969

9.  Clinical Benefit of Preoperative Exercise and Nutritional Therapy for Patients Undergoing Hepato-Pancreato-Biliary Surgeries for Malignancy.

Authors:  Hiroki Nakajima; Yukihiro Yokoyama; Takayuki Inoue; Motoki Nagaya; Yota Mizuno; Izumi Kadono; Kimitoshi Nishiwaki; Yoshihiro Nishida; Masato Nagino
Journal:  Ann Surg Oncol       Date:  2018-10-26       Impact factor: 5.344

View more
  2 in total

1.  Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.

Authors:  Brett L Ecker; Colin M Court; Quisette P Janssen; Alice J Tao; Michael I D'Angelica; Jeffrey A Drebin; Mithat Gonen; Eileen M O'Reilly; William R Jarnagin; Alice C Wei
Journal:  J Am Coll Surg       Date:  2022-04-05       Impact factor: 6.532

2.  Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.

Authors:  Pedro Luiz Serrano Uson Junior; Leonardo Carvalho; Milena Lourenço Coleta Fernandes; Gehan Botrus; Rodrigo de Souza Martins; Elaine Ferreira da Silva; Sarah Silva Mello Batista Dos Santos; Leticia Taniwaki; Patrícia Taranto; Ana Carolina Pereira Dutra; João Bosco de Oliveira Filho; Sergio Eduardo Alonso Araujo; Fernando Moura
Journal:  Sci Rep       Date:  2022-08-10       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.